Form 4: Tarsus Pharmaceuticals Director Katherine Goodrich Receives Annual Equity Awards

Tarsus Pharmaceuticals, Inc. director Katherine Goodrich was granted annual equity awards comprising stock options and restricted stock units as part of her non-employee director compensation.

Summary

• Katherine Goodrich, a Director at Tarsus Pharmaceuticals, Inc. (TARS), received equity awards on June 12, 2025.
• The awards include 4,540 stock options with an exercise price of $40.95 per share.
• These stock options are scheduled to vest in full on the one-year anniversary of the grant date, specifically June 12, 2026, contingent upon her continuous service as a non-employee director.
• The stock options have an expiration date of June 11, 2035.
• Additionally, Ms. Goodrich was granted 2,954 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Company's common stock.
• The RSUs will also vest in full on the one-year anniversary of the grant date, June 12, 2026, subject to her continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This Form 4 reports routine director compensation, which is a positive for aligning interests but does not indicate any significant new operational or financial developments for the company.

Positives

• The granting of equity awards to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard practice for compensating non-employee directors, reflecting a typical corporate governance structure.

Risks

• The vesting of both the stock options and Restricted Stock Units is subject to Katherine Goodrich's continuous service as a non-employee director, meaning the awards could be forfeited if her service ceases before the vesting date.

Future Outlook

The document indicates future vesting of equity awards on June 12, 2026, contingent on the director's continuous service, which is a standard condition for such compensation.

Industry Context

The granting of stock options and restricted stock units to non-employee directors is a common compensation practice across various industries, including the pharmaceutical sector, to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The structure of this equity grant, including the mix of stock options and RSUs with a one-year cliff vesting, is consistent with typical non-employee director compensation packages observed in the biotechnology and pharmaceutical industries.
• The exercise price of the stock options being at or above the market price on the grant date (implied by the lack of a discount) is also standard practice for incentive-based compensation.

Corporate Governance

Related Party Transactions

• The equity awards granted to Katherine Goodrich, a director of Tarsus Pharmaceuticals, Inc., constitute a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options and Restricted Stock Units are scheduled to vest on June 12, 2026, provided Katherine Goodrich maintains continuous service as a non-employee director.

Key Dates

Keywords

Tarsus Pharmaceuticals, TARS, SEC Form 4, Insider Transaction, Director Compensation, Equity Award, Stock Option, Restricted Stock Units, RSU, Corporate Governance